Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Trial Identifier: D8532C00002
Sponsor: AstraZeneca
NCTID:: NCT05790304
Start Date: February 2023
Primary Completion Date: February 2024
Study Completion Date: February 2024
Condition: Liver, Pancreas & Gallbladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BG Sofia, BG, 1612
SK Bratislava, SK, 831 01
US, CA Rialto, CA, US, 92377
US, TX San Antonio, TX, US, 78229
US, TX San Antonio, TX, US, 78215